Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tcg Crossover
BioCentury | Aug 22, 2024
Finance
Venture Report: Megarounds for BridgeBio newco, Pathalys and the latest from Versant
$300M raise for rare disease company GondolaBio headlines the week’s biggest venture rounds
BioCentury | Jan 4, 2024
Finance
How TCG X will navigate evolving crossover dynamics with new $1B fund
Led by Chen Yu, firm launched in 2021 exceeds planned target for Fund II after string of M&A deals brings returns
BioCentury | Aug 25, 2022
Deals
Aug. 25 Quick Takes: Radiopharma company Aktis tops off series A
Plus Takeda’s dengue vaccine gets first global approval, and updates from Pfizer, AstriVax, Ordaos, Zelluna and more
BioCentury | Aug 1, 2022
Emerging Company Profile
Structure: Replacing biologics with small molecules
Backed by a syndicate that includes top China investors, Structure is replacing GPCR-targeted biologics with small molecules to overcome global access barriers
BioCentury | Feb 24, 2022
Finance
Fresh off Amgen deal, Plexium raises $102M for degrader platform
BVF Partners, TCG Crossover co-lead funding to advance Plexium’s cell- and DEL-based degrader discovery tech
BioCentury | Nov 10, 2021
Product Development
Nov. 9 Quick Takes: Arbor’s $215M round attracts Temasek, Ally Bridge, TCG
Janssen trims Alkermes deal, EU moves to standardize HTA, plus GE Healthcare, Biogen, Amylyx and more
BioCentury | Jun 10, 2021
Finance
Cytokine companies Synthekine, Bright Peak each tap crossovers for megarounds
Engineered cytokine companies Synthekine and Bright Peak each raised nine-figure crossover rounds Thursday, setting both companies up as candidates for public offerings in the coming months. Menlo
BioCentury | May 13, 2021
Product Development
May 12 Quick Takes: Biogen-TMS in stroke deal; plus Minerva, Autobahn-Astellas, Emergent, Magenta, Fosun-BioNTech
Biogen Inc. (NASDAQ:BIIB) is exercising an option to acquire a next-generation thrombolytic agent from TMS Co. Ltd. The move comes after the Japanese company showed TMS-007 reopened blood vessels and
BioCentury | May 3, 2021
Product Development
Affinia readies its engineered AAVs for the clinic with $110M B round led by crossovers EcoR1, Farallon
Fund-raise by AveXis veterans Modi, Nolan comes a week after AAV play Capsida’s launch
BioCentury | Apr 20, 2021
Finance
Led by Chen Yu, Column Group-affiliated TCG Crossover closes first fund with $824M
Former Vivo managing partner has earmarked 15% for China deals
Items per page:
1 - 10 of 13